Abstract: Compounds of the formula: ##STR1## useful in treating dermal inflammation in warm-blooded animals are provided.

Abstract: Transient, orally active thiazolidine type prodrug forms of conventional, natural and synthetic ketosteroidal sex hormones, e.g., of progesterone, testosterone, and the like, are disclosed. The subject compounds can be prepared by known methods, for example, by reacting the corresponding 3-keto or 3,20-diketo steroids with a thiazolidine-forming reagent such as an L-cysteine alkyl ester.

Abstract: Highly water-soluble erythromycin A derivatives wherein the desosamine moiety is quaternized with an acyloxy-, benzoyloxy- or alkoxycarbonyl-(or carboxy)-acylmethyl iodide, bromine or chloride and esterified in the 2-position with loweralkyl or --(CH.sub.2).sub.n CO.sub.2 R", wherein R" is H, loweralkyl or substituted loweralkyl and n is an integer from 1-5. These new esters readily convert to erythromycin A upon administration to warm-blooded animals.

Abstract: Novel pyridiniumaldoximes having micellar characteristics are useful in the deactivation of organophosphates. Fast and effective detoxification of areas and equipment contaminated with organophosphate pesticides and insecticides results from use of the reagents.

Abstract: Novel 3,2'-spiro(1',3'-thiazolidine) compounds which are transient prodrug forms of known anti-inflammatory corticosteroids are disclosed. The subject compounds can be prepared by known methods, for example, by reacting the corresponding 3-keto steroids with a thiazolidine forming reagent such as an L-cysteine alkyl ester. Preferred compounds are derived from such known anti-inflammatory corticosteroids as cortisone acetate, hydrocortisone, prednisone, prednisolone and the like.

Abstract: Transient, C-21 and/or C-17 esteramide prodrugs of the anti-inflammatory corticosteroids, prepared by esterification of hydroxy steroids, are disclosed.

Abstract: Transient, topically active thiazolidine type prodrug forms of progesterone are disclosed.

Abstract: There are described compounds of formula I, ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are the same or different and each represent hydrogen, halogen, hydroxy, alkyl C 1 to 6, alkoxy C 1 to 6, hydroxy-alkoxy C 1 to 6, or alkoxy C 1 to 6-alkoxy C 1 to 6,X is a straight or branched C 2 to 10 hydrocarbon chain which may be substituted by an --OH group,Q is a group --CHR--ZR is hydrogen, alkyl C 1 to 8, phenyl, or alkoxy (C 1 to 8)-carbonyl,Z is a group --O--CO--Ra, --CO--ORa or --CONRbRc,Ra is cyclohexyl or cyclopentyl; straight or branched alkyl C 1 to 12, which is optionally substituted by cyclohexyl or cyclopentyl; alkenyl C 2 to 6, which is optionally substituted by phenyl; or, when Z is --CO--ORa, hydrogen, andRb and Rc, which are the same or different, are each alkyl C 1 to 12.There are also described processes for making the compounds, and pharmaceutical, e.g. anti-allergic, compositions containing the compounds.

Abstract: There is provided, novel, transient, pro-drug forms of phenylbutazone and oxyphenbutazone having the following formula: ##STR1## wherein R represents a member selected from the group consisting of a C.sub.1 -C.sub.2 O-alkylsulfonyl group, an aryl(phenyl, p-tolyl, naphthyl)sulfonyl group, a nicotinoyl group, an iso-nicotinoyl group, a picolinoyl group, an N-protected naturally occurring amino acid residue, wherein the protective group on the amino group of the amino acid residue is removable via hydrogenolysis or hydrolysis, and an amino acid residue containing a C.sub.1 -C.sub.2 N,N-dialkylamino or a C.sub.4 -C.sub.6 cycloalkylamino group. ##STR2## wherein X and Y each represent a member selected from the group consisting of a hydrogen atom and a --OR.sub.1 group, with the proviso that either X or Y is a hydrogen atom and that R.sub.2 is a member selected from the same or different groups represented by R.sub.1 ; and wherein R.sub.

Abstract: Compounds having the formula: ##STR1## wherein R represents hydrogen or a straight or branched C.sub.1 -C.sub.5 alkyl group; and R.sub.1 and R.sub.2 which may be the same or different represent an acyl member which is alkanoyl having 1-22 carbon atoms, alkenoyl having one or two double bonds and having 4-22 carbon atoms, cycloalkyl-C.sub.n H.sub.2n ##STR2## having a total of 4-10 carbon atoms of which 3-7 are ring carbon atoms in cycloalkyl and wherein n is zero, one, or two, phenoxyacetyl, naphthalenecarbonyl, pyridinecarbonyl, phenyl-C.sub.n H.sub.2n ##STR3## wherein n is zero, one or two and phenyl is unsubstituted or is substituted by 1-3 alkyl having 1-4 carbon atoms, alkoxy having 1-4 carbon atoms, halo, trifluoromethyl, dialkylamino having 2-8 carbon atoms, or alkanoylamino having 1-6 carbon atoms groups; ##STR4## wherein R.sub.3 may be hydrogen, hydroxyl or a member defined in accordance with R.sub.1 and R.sub.2 above or ##STR5## wherein R.sub.8 and R.sub.

Abstract: Intraocular pressure in warm-blooded animals is reduced by topically applying to the eye thereof, an effective ophthalmologically acceptable amount of a compound of the formula: ##STR1## wherein R represents a member selected from the group consisting of hydrogen or a C.sub.1 -C.sub.5 straight or branched alkyl group; and wherein R.sub.1 and R.sub.